JP2006508098A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508098A5 JP2006508098A5 JP2004548931A JP2004548931A JP2006508098A5 JP 2006508098 A5 JP2006508098 A5 JP 2006508098A5 JP 2004548931 A JP2004548931 A JP 2004548931A JP 2004548931 A JP2004548931 A JP 2004548931A JP 2006508098 A5 JP2006508098 A5 JP 2006508098A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound according
- group
- hydrogen
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 49
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- -1 methylenedioxy group Chemical group 0.000 claims description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
- 239000000651 prodrug Substances 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 150000008163 sugars Chemical class 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000031481 Pathologic Constriction Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 2
- 206010057644 Testis cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000028169 periodontal disease Diseases 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 230000003595 spectral effect Effects 0.000 claims 2
- 208000037804 stenosis Diseases 0.000 claims 2
- 230000036262 stenosis Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000003120 testicular cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 150000002148 esters Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GVKXFVCXBFGBCD-TURJJOHXSA-N COC1OCC(C(CO)O)OC1Oc1cc(O[C@@]([C@@H]([C@H]([C@H]2O)C(OC)=O)c3ccccc3)([C@@]22O)c(cc3)ccc3OC)c2c(OC)c1 Chemical compound COC1OCC(C(CO)O)OC1Oc1cc(O[C@@]([C@@H]([C@H]([C@H]2O)C(OC)=O)c3ccccc3)([C@@]22O)c(cc3)ccc3OC)c2c(OC)c1 GVKXFVCXBFGBCD-TURJJOHXSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/291,863 US6710075B2 (en) | 2000-07-05 | 2002-11-08 | Therapeutic compounds and methods |
| US10/291,863 | 2002-11-08 | ||
| PCT/AU2003/001463 WO2004041812A1 (en) | 2002-11-08 | 2003-11-06 | Therapeutic compounds and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006508098A JP2006508098A (ja) | 2006-03-09 |
| JP2006508098A5 true JP2006508098A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2010-08-26 |
| JP4847014B2 JP4847014B2 (ja) | 2011-12-28 |
Family
ID=32312131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004548931A Expired - Fee Related JP4847014B2 (ja) | 2002-11-08 | 2003-11-06 | 治療化合物および方法 |
Country Status (5)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5249508B2 (ja) | 2006-11-06 | 2013-07-31 | 三菱重工業株式会社 | 軌道系交通システム |
| US9464067B2 (en) * | 2011-06-16 | 2016-10-11 | Katholieke Universiteit Leuven K.U. Leuven R & D | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases |
| ES2863985T3 (es) | 2012-12-14 | 2021-10-13 | Korea Res Inst Chemical Tech | Nuevo compuesto, sal farmacéuticamente aceptable o isómero óptico del mismo, método para prepararlo y composición farmacéutica para la prevención o el tratamiento de enfermedades virales que lo contienen como ingrediente activo |
| CN109476648B (zh) | 2016-06-06 | 2022-09-13 | 豪夫迈·罗氏有限公司 | 司维司群抗体-药物缀合物和使用方法 |
| TW202448874A (zh) | 2020-04-20 | 2024-12-16 | 瑞士商諾華公司 | 抗病毒性1,3-二氧代茚化合物 |
| KR20230024887A (ko) | 2020-04-20 | 2023-02-21 | 노파르티스 아게 | 항바이러스성 1,3-디-옥소-인덴 화합물 |
| CN115385924B (zh) * | 2022-10-06 | 2023-10-13 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种具有抗肿瘤活性的环戊烷苯并呋喃类化合物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19835325A1 (de) * | 1998-08-05 | 2000-02-10 | Bayer Ag | Verwendung von Cyclopentabenzofuran-Derivaten zur Bekämpfung von NF-kB abhängigen Krankheiten |
| AUPQ866500A0 (en) * | 2000-07-05 | 2000-08-03 | Exgenix Operations Pty Ltd | Therapeutic compounds and methods |
-
2003
- 2003-11-06 AU AU2003277988A patent/AU2003277988A1/en not_active Abandoned
- 2003-11-06 JP JP2004548931A patent/JP4847014B2/ja not_active Expired - Fee Related
- 2003-11-06 WO PCT/AU2003/001463 patent/WO2004041812A1/en active Application Filing
- 2003-11-06 EP EP03769069A patent/EP1569928A4/en not_active Withdrawn
- 2003-11-06 CA CA002504999A patent/CA2504999A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4544446B2 (ja) | ｓＰＬＡ２阻害作用を有するピロロ［１，２−ｂ］ピリダジン誘導体 | |
| EP2069342B1 (fr) | Derives de 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, leur preparation et leur application en therapeutique | |
| ES2330636T3 (es) | Derivados amida del acido 3-oxo-1,3-dihidro-indazol-2-carboxilico como inhibidores de la fosfolipasa. | |
| WO2004096806A1 (ja) | 縮合イミダゾール誘導体 | |
| CA2917965C (fr) | Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| HU229314B1 (en) | Polymorphs of an epothilone analog | |
| JP2013522325A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| CA2753135A1 (fr) | Derives de pyrazolo[1,5-.alpha.]-1,3,5-triazines, leur preparation et leur application en therapeutique | |
| EP3164393B1 (fr) | Dérivés de flavaglines | |
| TW200906401A (en) | Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof | |
| JP2008531713A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP2006508098A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| FR2917413A1 (fr) | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique | |
| WO2006101081A1 (ja) | ５－［２－アミノ－４－（２－フリル）ピリミジン－５－イル］－１－メチルピリジン－２（１ｈ）－オンの結晶及びその製造方法 | |
| EP2880023A1 (fr) | Derives de griseofulvine | |
| CN119522098A (zh) | 用于治疗精神障碍的吡啶衍生物 | |
| WO2006016067A2 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer | |
| ES2866324T3 (es) | Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria | |
| JP2005531602A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JP3215850B2 (ja) | ハロアルコキシ基を含有するピロロ［３，２―ｃ］キノリン誘導体及び薬学的に許容されるその塩 | |
| EP1897880A1 (en) | 1,3-benzothiazinone derivative and use thereof | |
| ES2334712T3 (es) | Compuestos precursores antiritmicos, procedimientos de sintesis y uso de los mismos. | |
| JP7379381B2 (ja) | リナグリプチンおよびその塩の製造のための中間体およびプロセス | |
| JPH0560478B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPH08225534A (ja) | 免疫抑制シクロリグナン誘導体 |